John Mullinax

8PUBLICATIONS
48CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 01, 2026
Sarcopenia After Neoadjuvant Radiation Is Associated With Increased Length of Stay Following Resection of Retroperitoneal Sarcoma.

|Nov 30, 2025
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.

George Coukos, Marco Donia, Brian R Gastman

|Jan 21, 2025
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

Simon Turcotte, Marco Donia, Brian Gastman

|Jul 27, 2024
Oncolytic Viral Therapy in Osteosarcoma.

Thomas Karadimas, Thien Huong Huynh, Chloe Chose

|Oct 06, 2023
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.

MacLean S Hall, Jamie K Teer, Xiaoqing Yu

|Oct 10, 2022
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

MacLean S Hall, John E Mullinax, Cheryl A Cox

Pageof 2

Frequent Collaborators

2 joint publications

Michael Jain

2 joint publications

Xuefeng Wang

2 joint publications

Christina Bachmeier

2 joint publications

Aleksandr Lazaryan